MDS-175: Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial

Autor: Platzbecker, Uwe, Fenaux, Pierre, Mufti, Ghulam J., Garcia-Manero, Guillermo, Komrokji, Rami S., Buckstein, Rena, Diez-Campelo, María, Finelli, Carlo, Sekeres, Mikkael A., Selleslag, Dominik, DeZern, Amy E., Quesnel, Bruno, Beyne-Rauzy, Odile, Voso, Maria Teresa, Greenberg, Peter L., Zeidan, Amer M., Adès, Lionel, Verma, Amit, Savona, Michael R., Laadem, Abderrahmane, Ito, Rodrigo, Zhang, Jennie, Rampersad, Anita, Morison, Jessica, Louis, Chrystal, Linde, Peter G., Santini, Valeria
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2020 20 Supplement 1:S318-S318
Databáze: ScienceDirect
Externí odkaz: